샘플 요청 목록

 카트 문의
시장보고서
상품코드
1779744

세계의 세포 면역요법 시장

Cellular Immunotherapy
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 386 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 세포 면역요법 시장은 2030년까지 336억 달러에 달할 전망

2024년에 109억 달러로 추정되는 세계의 세포 면역요법 시장은 2024-2030년의 분석 기간에 CAGR 20.6%로 성장하며, 2030년에는 336억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 CAR T 세포치료는 CAGR 24.2%를 기록하며, 분석 기간 종료시에는 118억 달러에 달할 것으로 예측됩니다. 수지상세포 요법 부문의 성장률은 분석 기간의 CAGR로 21.0%로 추정됩니다.

미국 시장은 30억 달러로 추정, 중국은 CAGR 28.2%로 성장할 것으로 예측

미국의 세포 면역요법 시장은 2024년에 30억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 81억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 28.2%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 16.1%와 18.6%로 예측됩니다. 유럽에서는 독일이 CAGR 약 17.3%로 성장할 것으로 예측됩니다.

세계의 세포 면역요법 시장 - 주요 동향과 촉진요인 정리

세포 면역 요법은 암 치료에 어떤 혁명을 가져올 것인가?

세포면역치료는 인체의 면역체계를 활용하여 악성세포를 표적으로 삼아 파괴하는 것으로 암 치료의 판도를 바꾸고 있습니다. 세포면역치료는 화학요법이나 방사선 치료와 같은 기존 치료법과 달리 T세포나 자연살해(NK) 세포와 같은 인공 면역세포를 활용하여 보다 표적화된 장기적인 반응을 기대할 수 있는 치료법입니다. 이 분야에서 가장 주목할 만한 발전은 CAR-T 세포 치료로, 백혈병이나 림프종과 같은 혈액암 치료에 놀라운 성공을 거두고 있습니다. 정밀의료에 대한 관심이 높아지면서 세포면역치료는 자가면역질환, 감염질환 등 종양학에 국한되지 않는 다양한 질환의 치료로 진화하고 있습니다. 유전공학과 생명공학의 발달로 연구자들은 부작용을 최소화하면서 환자의 예후를 개선하는 차세대 세포치료제를 개발할 수 있게 되었습니다. 규제 당국의 승인이 확대되고 임상시험에서 유망 결과를 얻음에 따라 세포 면역 요법의 채택은 향후 수년간 크게 증가할 것으로 예측됩니다.

세포면역치료에 대한 수요가 증가하는 이유는?

암 발병률 증가와 기존 치료법의 한계가 세포면역치료에 대한 수요를 촉진하고 있습니다. 환자와 의료진은 부작용이 적고 효과가 높은 대체요법을 적극적으로 찾고 있습니다. 또한 초기 CAR-T 치료의 성공은 새로운 세포 기반 치료법 개발에 대한 투자의 물결을 일으켜 면역 치료의 적용 범위를 넓히고 있습니다. 또한 CRISPR, 합성생물학 등 유전자 편집 기술의 발전으로 과학자들은 면역세포의 기능성과 특이성을 향상시킬 수 있게 되었습니다. 동종세포치료와 '기성품' 세포치료의 출현은 환자 유래 자가세포치료에 비해 확장 가능하고 비용 효율적인 치료 솔루션을 제공한다는 점에서 시장 성장을 가속하는 중요한 요인으로 작용하고 있습니다. 이러한 획기적인 발전은 환자 접근성을 향상시킬 뿐만 아니라 세포 면역 요법을 보다 실용적이고 광범위한 치료 옵션으로 만들고 있습니다.

세포면역치료제 시장을 주도하는 지역은?

북미가 세포면역치료제 시장을 독점하고 있으며, 강력한 R&D 투자, 탄탄한 생명공학 부문, 빠른 약사 승인 등이 그 원동력이 되고 있습니다. 특히 미국은 CAR-T 치료제의 상용화를 선도하고 있으며, 이미 혈액악성종양에 대한 여러 치료제가 FDA 승인을 받았습니다. 주요 제약사, 연구기관, 첨단 의료 인프라가 존재하여 이 지역 시장 리더십을 더욱 강화하고 있습니다. 유럽은 독일, 영국, 프랑스 등 국가들이 임상 연구와 치료법 채택에서 큰 진전을 이루었고, 이후 먼지를 뒤집어쓰고 있습니다. 한편, 아시아태평양은 중국, 일본, 한국 등 각국의 정부 지원 증가, 암 발병률 상승, 바이오테크놀러지 역량 확대로 인해 급속한 성장세를 보이고 있습니다. 이들 지역의 규제 당국은 승인 절차를 간소화하고 혁신적인 세포 기반 치료제에 대한 신속한 접근을 촉진하고 있습니다.

시장 성장을 가속하는 주요 요인은 무엇인가?

세포면역치료제 시장의 성장은 세포공학의 발전, 암 이외의 적응증 확대, 바이오의약품 연구개발에 대한 투자 증가 등 여러 요인에 의해 이루어지고 있습니다. 또한 세포면역치료는 환자 개개인의 유전자 및 면역학적 프로파일에 맞춘 환자 맞춤형 치료법 개발이 가능하므로 맞춤형 의료로의 전환도 중요한 역할을 하고 있습니다. 또한 제조의 확장성을 높이고 치료 비용을 절감하기 위한 지속적인 노력은 이러한 치료법을 더욱 친숙하게 만들고 있습니다. 자동화, AI를 활용한 분석, 바이오프로세스의 최적화를 통해 세포치료제 생산의 효율을 높이고, 더 높은 효율성과 광범위한 시장 도입을 보장하고 있습니다. 이 분야가 새로운 기술과 용도의 확대로 계속 진화하고 있는 가운데, 세포면역치료는 정밀의료와 면역종양학의 미래를 형성하는 데 있으며, 매우 중요한 역할을 할 것으로 기대되고 있습니다.

부문

치료법(CAR T 세포치료, 수지상세포 요법, NK 세포치료, TIL 요법, 기타 치료법), 적응증(B세포 악성 종양, 전립선암 적응증, 간암 적응증, 신세포암 적응증, 기타 적응증), 최종사용자(병원 최종사용자, 암연구소 최종사용자, 기타 최종사용자)

조사 대상 기업의 예

  • AbbVie Inc.
  • Adicet Bio, Inc.
  • Aduro Biotech, Inc.
  • Agenus Inc.
  • Amgen Inc.
  • Arcellx, Inc.
  • AstraZeneca PLC
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celyad Oncology SA
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.(Kite Pharma)
  • GlaxoSmithKline plc.
  • Immunocore Holdings plc
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • Kymab Ltd.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.11

Global Cellular Immunotherapy Market to Reach US$33.6 Billion by 2030

The global market for Cellular Immunotherapy estimated at US$10.9 Billion in the year 2024, is expected to reach US$33.6 Billion by 2030, growing at a CAGR of 20.6% over the analysis period 2024-2030. CAR T Cell Therapy, one of the segments analyzed in the report, is expected to record a 24.2% CAGR and reach US$11.8 Billion by the end of the analysis period. Growth in the Dendritic Cell Therapy segment is estimated at 21.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 28.2% CAGR

The Cellular Immunotherapy market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.1 Billion by the year 2030 trailing a CAGR of 28.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.1% and 18.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.3% CAGR.

Global Cellular Immunotherapy Market - Key Trends & Drivers Summarized

How Is Cellular Immunotherapy Revolutionizing Cancer Treatment?

Cellular immunotherapy is transforming the landscape of cancer treatment by harnessing the body's immune system to target and destroy malignant cells. Unlike traditional therapies such as chemotherapy and radiation, cellular immunotherapy leverages engineered immune cells, such as T-cells and natural killer (NK) cells, to provide a more targeted and potentially long-lasting response. Among the most notable advancements in this field are CAR-T cell therapies, which have shown remarkable success in treating blood cancers like leukemia and lymphoma. With the increasing focus on precision medicine, cellular immunotherapy is evolving to treat a wider range of conditions beyond oncology, including autoimmune disorders and infectious diseases. Advances in genetic engineering and biotechnology are enabling researchers to develop next-generation cell therapies that improve patient outcomes while minimizing adverse effects. As regulatory approvals expand and clinical trials yield promising results, the adoption of cellular immunotherapy is expected to rise significantly in the coming years.

Why Is the Demand for Cellular Immunotherapy Increasing?

The increasing incidence of cancer and the limitations of conventional treatments are driving demand for cellular immunotherapy. Patients and healthcare providers are actively seeking alternative therapies that offer higher efficacy with fewer side effects. Moreover, the success of early CAR-T therapies has spurred a wave of investment in the development of new cell-based treatments, broadening the scope of immunotherapy applications. Additionally, growing advancements in gene editing technologies such as CRISPR and synthetic biology are enabling scientists to enhance the functionality and specificity of immune cells. The emergence of allogeneic or “off-the-shelf” cellular therapies is also a key factor driving market growth, as they offer scalable and cost-effective treatment solutions compared to patient-derived autologous therapies. These breakthroughs are not only improving patient accessibility but also making cellular immunotherapy a more viable and widespread treatment option.

Which Regions Are Leading the Cellular Immunotherapy Market?

North America dominates the cellular immunotherapy market, fueled by strong R&D investments, a robust biotechnology sector, and early regulatory approvals. The United States, in particular, has led the commercialization of CAR-T therapies, with several FDA-approved treatments already in use for hematologic malignancies. The presence of leading pharmaceutical companies, research institutions, and advanced healthcare infrastructure further bolsters the region’s market leadership. Europe follows closely behind, with countries such as Germany, the UK, and France making significant strides in clinical research and therapy adoption. Meanwhile, the Asia-Pacific region is experiencing rapid growth due to increased government support, rising cancer prevalence, and expanding biotechnology capabilities in countries like China, Japan, and South Korea. Regulatory agencies in these regions are streamlining approval pathways, facilitating faster access to innovative cell-based treatments.

What Are the Key Factors Driving Market Growth?

The growth in the Cellular Immunotherapy market is driven by several factors, including advancements in cell engineering, expanding indications beyond oncology, and increasing investment in biopharmaceutical R&D. The shift toward personalized medicine is also playing a crucial role, as cellular immunotherapy enables the development of patient-specific treatments tailored to individual genetic and immunological profiles. Moreover, ongoing efforts to enhance manufacturing scalability and reduce treatment costs are making these therapies more accessible. The rise of automation, AI-driven analytics, and bioprocess optimization is streamlining cell therapy production, ensuring higher efficiency and broader market adoption. As the field continues to evolve with novel technologies and expanded applications, cellular immunotherapy is expected to play a pivotal role in shaping the future of precision medicine and immuno-oncology.

SCOPE OF STUDY:

The report analyzes the Cellular Immunotherapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Other Therapies); Indication (B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication, Renal Cell Carcinoma Indication, Other Indications); End-Use (Hospitals End-Use, Cancer Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Adicet Bio, Inc.
  • Aduro Biotech, Inc.
  • Agenus Inc.
  • Amgen Inc.
  • Arcellx, Inc.
  • AstraZeneca PLC
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Celyad Oncology SA
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc. (Kite Pharma)
  • GlaxoSmithKline plc.
  • Immunocore Holdings plc
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • Kymab Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cellular Immunotherapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in CAR-T and TCR Therapies Propels Growth of the Cellular Immunotherapy Market
    • Expansion of Oncology Indications Accelerates Therapy Pipeline Development
    • Advancements in Gene Editing Tools Strengthen Cell Engineering Capabilities
    • Increasing Investment in Personalized and Precision Medicine Spurs Innovation
    • Growing Role of Tumor Microenvironment Research Expands Therapeutic Potential
    • Emergence of Allogeneic Therapies Enhances Scalability and Market Access
    • Improved Manufacturing Technologies Drive Cost Efficiency and Product Consistency
    • Strategic Collaborations and Licensing Deals Boost R&D Productivity
    • Expansion of Academic and Industry Consortia Enhances Translational Research
    • Integration of AI and Bioinformatics in Target Identification Enhances Therapy Design
    • Development of Combination Immunotherapy Protocols Expands Efficacy Profiles
    • Growth in Clinical Trial Activity Across Hematological and Solid Tumors Strengthens Commercial Pipeline
    • Rising Interest in Cell Banks and Off-the-Shelf Therapies Accelerates Adoption
    • Technological Advancements in Cell Expansion and Cryopreservation Support Global Access
    • Adoption of Decentralized Manufacturing Models Broadens Regional Production Capabilities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cellular Immunotherapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cellular Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cellular Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cellular Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for CAR T Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for CAR T Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for CAR T Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Dendritic Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Dendritic Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Dendritic Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for NK Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for NK Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for NK Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for TIL Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for TIL Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for TIL Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for B-Cell Malignancies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for B-Cell Malignancies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for B-Cell Malignancies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Prostate Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Prostate Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Prostate Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Liver Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Liver Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Liver Cancer Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Renal Cell Carcinoma Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Renal Cell Carcinoma Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Renal Cell Carcinoma Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Cancer Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Cancer Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Cancer Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Cellular Immunotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Cellular Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Cellular Immunotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Australia 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: India 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: South Korea 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Cellular Immunotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Cellular Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Latin America 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Argentina 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Brazil 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Mexico 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Cellular Immunotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Cellular Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Middle East 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Iran 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Israel 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: UAE 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Cellular Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Cellular Immunotherapy by Therapy - CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Cellular Immunotherapy by Therapy - Percentage Breakdown of Value Sales for CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy and Other Therapies for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Cellular Immunotherapy by Indication - Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Cellular Immunotherapy by Indication - Percentage Breakdown of Value Sales for Other Indications, B-Cell Malignancies, Prostate Cancer Indication, Liver Cancer Indication and Renal Cell Carcinoma Indication for the Years 2015, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Cellular Immunotherapy by End-Use - Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Africa 15-Year Perspective for Cellular Immunotherapy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Cancer Institutes End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제